Direct determination of protein binding of phenytoin in serum by high-performance liquid chromatography

Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins

This report describes a new method for the determination of protein binding and relative protein binding (ratio of f(u) for different species) for compounds strongly bound to proteins. The method used is based on the distribution of the drug in plasma water, plasma proteins, and blood cells. Incubations were performed in diluted plasma. In diluted plasma, the erythrocyte/plasma distribution was determined with greater precision than in undiluted plasma. Formulae were derived for calculating f(u) in undiluted plasma based on the f(u) values determined in diluted plasma. These formulae are also valid in the event of more than one independent binding site in plasma. All incubations with plasma of different species were performed using rat erythrocyte suspensions, thereby making it possible for relative f(u) values in different species to be calculated without knowing the absolute free fractions. This method avoids the determination of the erythrocyte/buffer distribution in cases where it is sufficient to know relative f(u) values (e.g., exposure comparisons). Relative protein binding can also be quantified for compounds that tend to adsorb to surfaces of vials or test tubes, thus avoiding errors caused by adsorption when quantifying the drug in a protein-free aqueous solution. This method was validated by making comparisons of free fraction values obtained by the method herein described with those obtained by either ultrafiltration or equilibrium dialysis for two compounds that bind predominantly to albumin and another compound that binds to alpha(1)-acid glycoprotein. The results confirm our method produces identical free fractions in comparison with other established techniques. In addition, the range of applications of our method is much wider.

Direct injection HPLC method for the determination of phenylbutazone and oxyphenylbutazone in serum using a semipermeable surface column

A direct injection HPLC method has been developed for the determination of phenylbutazone and its active metabolite oxyphenylbutazone in serum using a semipermeable surface (SPS) column. The method is easy to perform and requires 20 microliters of a filtered serum sample. The chromatographic time is less than 13 min using a mobile phase of 15:85 v/v acetonitrile-0.05M phosphate buffer pH 7.5. The method was linear in the range 0.5-20 micrograms ml-1 (r > 0.99, n = 6) with R.S.D. less than 6%. Interday and intraday variability were found to be less than 8.3%. The limit of quantitation and detection were 0.5 and 0.25 microgram ml-1 (s/n > 3), respectively, for both drug and metabolite.

Phenytoin free fraction determination: comparison of an improved direct serum injection high-performance liquid chromatographic method to ultrafiltration coupled with fluorescence polarization immunoassay

Recent developments in restricted-access media (RAM) liquid chromatography make the simultaneous determination of total and free phenytoin concentrations possible by direct injection of drug-containing serum samples. A comparison of phenytoin free fraction determination by ultrafiltration coupled with fluorescence polarization immunoassay (TDX) to an improved direct injection RAM-HPLC method is presented. Our improved method differs from those previously reported with regard to column type, mobile-phase composition, and column temperature. Replicate samples analyzed by each method yielded similar values for serum phenytoin free fraction.

Direct injection analysis of carbamazepine and its active 10,11-epoxide metabolite in plasma by use of a semipermeable surface (SPS) silica column in LC

A semipermeable surface (SPS) silica column was applied for the simultaneous determination of carbamazepine (CBZ) and its active 10,11-epoxide metabolite (EPO) in plasma following direct injection in LC. The SPS packing material consists of an ODS ligand as the hydrophobic inner phase and a polyoxyethylene network as the hydrophilic outer phase. When a 5-microliters portion of intact plasma was injected onto the column using a mobile phase of phosphate buffer (pH 7.1, ionic strength 0.1)-acetonitrile (4:1, v/v), the plasma proteins were size-excluded, whereas the drug and its metabolite were retained and separated both from each other and from other commonly co-administered drugs such as phenobarbital (PB) and phenytoin (DPH). The calibration graphs (peak area vs concentration) of CBZ, EPO and PB were linear over the therapeutic range of plasma concentration (r greater than 0.998) with good relative standard deviations (RSD less than 3.98%, n = 5). The recoveries from plasma were almost complete (greater than 96.6%). The analysis time was 17 min. The method as developed was applied in studies on the time course of plasma concentrations of unchanged CBZ and EPO after i.v. administration of CBZ to the rat.

High-performance liquid chromatography packing materials for the analysis of small molecules in biological matrices by direct injection

The increasing demand on high-performance liquid chromatography to resolve mixtures of closely related components in complex biological matrices in less time with higher precision has led to the development of a variety of new high-performance liquid chromatography columns, which eliminate the need for sample preparation. These packings isolate small molecules from biological macromolecules on direct sample injection by exerting two separation mechanisms. They allow elution of all sample macromolecules with high recovery in one peak at the extraparticulate void, because of size-exclusion interactions with hydrophilic outer particulate surfaces. Simultaneously, these packings allow permeation and partitioning of small molecules on bonded-phases which are protected from contamination by macromolecules. The names given to these new packings include "internal surface reversed-phase", "shielded hydrophobic phase", "semipermeable surface", "dual zone material" and "mixed-functional phases". The fundamental principles behind each of the design concepts are reviewed, and applications are cited.

Methods of drug protein binding determinations

The determination of drug binding to proteins is carried out by several different approaches based mainly on separation methods. The most popular of these is equilibrium dialysis, which requires membranes devoid of non-specific adsorption to drugs. Ultrafiltration techniques have some advantage over dialysis due to shorter measurement times and the possibility of evaluation of the free drug under circumstances corresponding to physiological conditions. Now there is an increasing use of chromatographic techniques for fundamental studies on determination of binding parameters (number of sites, affinity constant). Different procedures can be chosen depending upon the biological materials available. They are based on the presence of the interacting species in the eluent, avoiding any chemical grafting.